CHIARINI, Francesca
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 6.068
AS - Asia 5.499
EU - Europa 2.176
SA - Sud America 771
AF - Africa 79
Continente sconosciuto - Info sul continente non disponibili 40
OC - Oceania 5
Totale 14.638
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.871
CN - Cina 1.939
SG - Singapore 1.768
IT - Italia 621
BR - Brasile 592
HK - Hong Kong 509
VN - Vietnam 393
GB - Regno Unito 379
KR - Corea 328
FI - Finlandia 252
SE - Svezia 190
BD - Bangladesh 183
RU - Federazione Russa 166
DE - Germania 137
FR - Francia 129
CA - Canada 90
ID - Indonesia 83
AR - Argentina 68
IN - India 64
NL - Olanda 64
LT - Lituania 56
MX - Messico 47
IQ - Iraq 36
EC - Ecuador 35
IE - Irlanda 34
JP - Giappone 31
TR - Turchia 26
AT - Austria 24
UA - Ucraina 23
ZA - Sudafrica 22
PL - Polonia 19
CR - Costa Rica 17
PK - Pakistan 17
AE - Emirati Arabi Uniti 16
CO - Colombia 14
ES - Italia 14
PY - Paraguay 14
VE - Venezuela 14
CL - Cile 12
KE - Kenya 12
CZ - Repubblica Ceca 10
UZ - Uzbekistan 10
IL - Israele 9
MA - Marocco 9
PE - Perù 9
SA - Arabia Saudita 9
NP - Nepal 8
TH - Thailandia 8
GT - Guatemala 7
HN - Honduras 7
JM - Giamaica 7
MY - Malesia 7
SC - Seychelles 7
TN - Tunisia 7
UY - Uruguay 7
BO - Bolivia 6
OM - Oman 6
PT - Portogallo 6
AL - Albania 5
BG - Bulgaria 5
CG - Congo 5
DO - Repubblica Dominicana 5
HR - Croazia 5
PA - Panama 5
PH - Filippine 5
RO - Romania 5
AU - Australia 4
DZ - Algeria 4
EG - Egitto 4
LK - Sri Lanka 4
PS - Palestinian Territory 4
SK - Slovacchia (Repubblica Slovacca) 4
AZ - Azerbaigian 3
BA - Bosnia-Erzegovina 3
CH - Svizzera 3
KG - Kirghizistan 3
KW - Kuwait 3
LA - Repubblica Popolare Democratica del Laos 3
LB - Libano 3
LV - Lettonia 3
MD - Moldavia 3
RS - Serbia 3
SY - Repubblica araba siriana 3
TT - Trinidad e Tobago 3
TW - Taiwan 3
AM - Armenia 2
BE - Belgio 2
BH - Bahrain 2
BY - Bielorussia 2
DK - Danimarca 2
ET - Etiopia 2
IR - Iran 2
JO - Giordania 2
KZ - Kazakistan 2
NG - Nigeria 2
NI - Nicaragua 2
NO - Norvegia 2
PR - Porto Rico 2
QA - Qatar 2
SN - Senegal 2
Totale 14.581
Salva come PNG Salva come JPEG
Città #
Hefei 1.197
Santa Clara 1.105
Singapore 941
Ashburn 932
San Jose 718
Hong Kong 502
Council Bluffs 367
Seoul 328
Dallas 309
Helsinki 229
London 216
The Dalles 157
Beijing 147
Los Angeles 141
Nyköping 140
Chicago 119
Ho Chi Minh City 118
Hanoi 109
Milan 97
Lauterbourg 75
Shanghai 74
Kent 70
Buffalo 65
Jakarta 65
New York 61
Munich 58
Fairfield 54
Moscow 53
Houston 51
Chandler 50
São Paulo 45
Boardman 44
Phoenix 44
Bologna 37
Dublin 33
Woodbridge 32
Parma 30
Southend 30
Amsterdam 29
Frankfurt am Main 28
Modena 28
Rome 27
Atlanta 26
Porto Alegre 25
Salt Lake City 25
Tampa 25
Indianapolis 24
Redondo Beach 24
Cambridge 23
Columbus 23
Nuremberg 21
San Anselmo 20
Seattle 20
Tokyo 20
Washington 19
Guangzhou 18
Orem 18
Rio de Janeiro 18
Wilmington 18
Brasília 17
Mexico City 17
North Bergen 17
Baghdad 16
Montreal 16
Reggio Emilia 16
Haiphong 15
Miano 15
San Rafael 15
Brooklyn 14
Chennai 14
Da Nang 14
Lansdowne 14
Plano 13
Stockholm 13
Warsaw 13
Naples 12
Quito 12
San José 12
Toronto 12
Belo Horizonte 11
Kilburn 11
Lancaster 11
Lappeenranta 11
Nairobi 11
Paris 11
San Francisco 11
Turku 11
Vancouver 11
Denver 10
Elk Grove Village 10
Jacksonville 10
San Diego 10
Tashkent 10
Vienna 10
Boston 9
Brescia 9
Chiswick 9
Curitiba 9
Dhaka 9
Erbil 9
Totale 9.822
Salva come PNG Salva come JPEG
Nome #
Dual inhibition of PI3K/mTOR signaling in chemoresistant AMLprimary cells. 330
Lamin A and the LINC complex act as potential tumor suppressors in Ewing Sarcoma 287
Antigene MYCN Silencing by BGA002 Inhibits SCLC Progression Blocking mTOR Pathway and Overcomes Multidrug Resistance 285
Crosstalks of GSK3 signaling with the mTOR network and effects on targeted therapy of cancer 271
Synergistic cytotoxic effects of bortezomib and CK2 inhibitor CX-4945 in acute lymphoblastic leukemia: Turning offthe prosurvival ER chaperone BIP/Grp78 and turning on the proapoptotic NF-κB 242
Effect of Erythropoietin Treatment on Lipid Signalling Pathways in Low-Risk MDS Patients 209
Molecular Signature of Biological Aggressiveness in Clear Cell Sarcoma of the Kidney (CCSK) 199
Assessment of the structural and functional characteristics of human mesenchymal stem cells associated with a prolonged exposure of morphine 198
Alteration of Akt activity increases chemotherapeutic drug and hormonal resistance in breast cancer yet confers an achilles heel by sensitization to targeted therapy 192
A COMBINATION OF BORTEZOMIB WITH CX-4945, A CASEIN KINASE 2 (CK2) INHIBITOR, HAS SYNERGISTIC CYTOTOXIC EFFECTS IN ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) CELL LINES 192
Cytotoxic activity of the casein kinase 2 inhibitor CX-4945 against T-cell acute lymphoblastic leukemia: targeting the unfolded protein response signaling 191
Activity of the novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235, against T-cell acute lymphoblastic leukemia 190
B-ALL Complexity: Is Targeted Therapy Still A Valuable Approach for Pediatric Patients? 187
A combination of temsirolimus, an allosteric mTOR inhibitor, with clofarabine as a new therapeutic option for patients with acute myeloid leukemia 185
Surface Charge Overrides Protein Corona Formation in Determining the Cytotoxicity, Cellular Uptake, and Biodistribution of Silver Nanoparticles 181
Preclinical testing of the Akt inhibitor triciribine in T-cell acute lymphoblastic leukemia 180
Synergistic induction of PI-PLCbeta1 signaling by azacitidine and valproic acid in high-risk myelodysplastic syndromes 180
Current treatment strategies for inhibiting mTOR in cancer 179
Pathobiology and Therapeutic Relevance of GSK-3 in Chronic Hematological Malignancies 176
Advances in understanding the acute lymphoblastic leukemia bone marrow microenvironment: From biology to therapeutic targeting 175
ASSESSMENT OF THE EFFECT OF SPHINGOSINE KINASE INHIBITORS ON APOPTOSIS, UNFOLDED PROTEIN RESPONSE AND AUTOPHAGY OF T-ACUTE LYMPHOBLASTIC LEUKEMIA CELLS: INDICATIONS FOR NOVEL THERAPEUTICS 174
Activity of the pan-class I phosphoinositide 3-kinase inhibitor NVP-BKM120 in T-cell acute lymphoblastic leukemia 173
Assessment of the effect of sphingosine kinase inhibitors on apoptosis,unfolded protein response and autophagy of T-cell acute lymphoblastic leukemia cells; indications for novel therapeutics 168
Magnesium and strontium-enriched bioactive glasses: superior biocompatibility and angiogenesis, beyond the gold standard 167
Age-Related Alterations Affecting the Chondrogenic Differentiation of Synovial Fluid Mesenchymal Stromal Cells in an Equine Model 165
The Role Played by Wnt/β-Catenin Signaling Pathway in Acute Lymphoblastic Leukemia 163
At the Nucleus of Cancer – How the Nuclear Envelope Controls Tumor Progression 163
AMP-dependent kinase/mammalian target of rapamycin complex 1 signaling in T-cell acute lymphoblastic leukemia: therapeutic implications 163
Cellular senescence in vascular wall mesenchymal stromal cells, a possible contribution to the development of aortic aneurysm 162
Targeting metabolic vulnerabilities and aberrant signal transduction pathways in paediatric T-cell Acute Lymphoblastic Leukaemia (T-ALL) 162
Activity of the selective IκB kinase inhibitor BMS-345541 against T-cell acute lymphoblastic leukemia: involvement of FOXO3a 161
Lamin A and Prelamin A Counteract Migration of Osteosarcoma Cells 160
New advances in targeting aberrant signaling pathways in T-cell acute lymphoblastic leukemia 160
Effect of Lenalidomide Treatment on Lipid Signalling Pathways in Low-Risk MDS Patients 160
Targeting the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin module for acute myelogenous leukemia therapy: from bench to bedside 157
Reduction of phosphoinositide-phospholipase C beta1 methylation predicts the responsiveness to azacitidine in high-risk MDS 156
Synergistic proapoptotic activity of recombinant TRAIL plus the Akt inhibitor perifosine in acute myeloid leukemia cells 156
13. PLCβ1a and PLCβ1b selective regulation and cyclin D3 modulation reduced by kinamycin F during k562 cell differentiation 155
Toxicity of antimony trioxide nanoparticles on human hematopoietic progenitor cells and comparison to cell lines 154
The Akt/mammalian target of rapamycin signal transduction pathway is activated in high-risk myelodysplastic syndromes and influences cell survival and proliferation 154
Therapeutic targeting of CK2 in acute and chronic leukemias 153
A role of PI-PLCb1 in G1/S transition in human erythroleukemia k562 cells 153
Targeted inhibition of mTORC1 and mTORC2 by active-site mTOR inhibitors has cytotoxic effects in T-cell acute lymphoblastic leukemia 153
Involvement of nuclear PLC{beta}1 in lamin B1 phosphorylation and G2/M cell cycle progression 152
Temsirolimus, an mTOR inhibitor, in combination with lower-dose clofarabine as salvage therapy for older patients with acute myeloid leukaemia: results of a phase II GIMEMA study (AML-1107) 152
GSK-3: a multifaceted player in acute leukemias 151
Advances in understanding the mechanisms of evasive and innate resistance to mTOR inhibition in cancer cells 149
Therapeutic potential of targeting sphingosine kinases and sphingosine 1-phosphate in hematological malignancies 148
The Combination of AHCC and ETAS Decreases Migration of Colorectal Cancer Cells, and Reduces the Expression of LGR5 and Notch1 Genes in Cancer Stem Cells: A Novel Potential Approach for Integrative Medicine 148
Targeting the phosphatidylinositol 3-kinase/Akt/mTOR signaling network in acute myelogenous leukaemia 146
Harnessing the PI3K/Akt/mTOR pathway in T-cell acute lymphoblastic leukemia: eliminating activity by targeting at different levels 145
Targeting Wnt/β-catenin and PI3K/Akt/mTOR pathways in T-cell acute lymphoblastic leukemia 145
Improving nelarabine efficacy in T cell acute lymphoblastic leukemia by targeting aberrant PI3K/AKT/mTOR signaling pathway 143
Two hits are better than one: targeting both phosphatidylinositol 3-kinase and mammalian target of rapamycin as a therapeutic strategy for acute leukemia treatment 142
Proapoptotic activity and chemosensitizing effect of the novel Akt inhibitor (2S)-1-(1H-Indol-3-yl)-3-[5-(3-methyl-2H-indazol-5-yl)pyridin-3-yl]oxypropan2-ami ne (A443654) in T-cell acute lymphoblastic leukemia 140
Autophagy in acute leukemias: a double-edged sword with important therapeutic implications 140
Proapoptotic activity and chemosensitizing effect of the novel Akt inhibitor perifosine in acute myelogenous leukemia cells 139
Temsirolimus, An Allosteric mTORC1 Inhibitor, Is Synergistic with Clofarabine in AML and AML Leukemia Initiating Cells 138
The Cutting Edge: The Role of mTOR Signaling in Laminopathies 138
Mutations and deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascades which alter therapy response 132
Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Cascade Inhibitors: How Mutations Can Result in Therapy Resistance and How to Overcome Resistance 130
Erucylphosphohomocholine, the first intravenously applicable alkylphosphocholine, is cytotoxic to acute myelogenous leukemia cells through JNK- and PP2A-dependent mechanisms 129
Differential Cytotoxicity of Surface-Functionalized Silver Nanoparticles in Colorectal Cancer and Ex-Vivo Healthy Colonocyte Models 129
K562 cell proliferation is modulated by PLCβ1 through a PKCα-mediated pathway 128
Understanding the Roles of the Hedgehog Signaling Pathway during T-Cell Lymphopoiesis and in T-Cell Acute Lymphoblastic Leukemia (T-ALL) 127
Cytotoxic activity of the novel Akt inhibitor, MK-2206, in T-cell acute lymphoblastic leukemia 124
Targeting the liver kinase B1/AMP-activated protein kinase pathway as a therapeutic strategy for hematological malignancies 124
Dual inhibition of class IA phoshatidylinositol 3-kinase and mTOR as a new therapeutic option for T-cell acute lymphoblastic leukemia 123
The unfolded protein response: a novel therapeutic target in acute leukemias 122
Implication of Cellular Senescence in Osteoarthritis: A Study on Equine Synovial Fluid Mesenchymal Stromal Cells 122
Targeting Signaling Pathways in T-cell acute lymphoblastic leukemia initiating cells 121
MYCN is a novel oncogenic target in pediatric T-cell acute lymphoblastic leukemia 120
The phosphatidylinositol 3-kinase/Akt/mTOR signaling network as a therapeutic target in acute myelogenous leukemia patients 119
Hh/Gli antagonist in acute myeloid leukemia with CBFA2T3-GLIS2 fusion gene 118
Therapeutic Targeting of mTOR in T-Cell Acute Lymphoblastic Leukemia: An Update 117
The novel Akt inhibitor, perifosine, induces caspase-dependent apoptosis and downregulates P-glycoprotein expression in multidrug-resisten human T-acute leukemia cells by a JNK-dependent mechanism 116
The Emerging Role of the Phosphatidylinositol 3-Kinase/Akt/Mammalian Target of Rapamycin Signaling Network in Cancer Stem Cell Biology 115
PI3K pan-inhibition impairs more efficiently proliferation and survival of T-cell acute lymphoblastic leukemia cell lines when compared to isoform-selective PI3K inhibitors 115
Inhibition of Methyltransferase DOT1L Sensitizes to Sorafenib Treatment AML Cells Irrespective of MLL-Rearrangements: A Novel Therapeutic Strategy for Pediatric AML 114
Lamin A acts a tumor suppressor in Ewing sarcoma promoting neural differentiation and reducing cell migration and invasion 113
The cyclin-dependent kinase inhibitor roscovitine and the nucleoside analog sangivamycin induce apoptosis in caspase-3 deficient breast cancer cells independent of caspase mediated P-glycoprotein cleavage 113
Increased NGAL (Lnc2) expression after chemotherapeutic drug treatment 111
Therapeutic targeting of Polo-like kinase-1 and Aurora kinases in T-cell acute lymphoblastic leukemia 109
Enhancing the effectiveness of nucleoside analogs with mTORC1 blockers to treat acute myeloid leukemia patients 108
Pediatric early T-cell precursor leukemia with NF1 deletion and high-sensitivity in vitro to tipifarnib 106
Dual Inhibition of Phosphatidylinositol 3-Kinase and Mammalian Target of Rapamycin: a Therapeutic Strategy for Acute Leukemias 105
Therapeutic potential of targeting mTOR in T-cell acute lymphoblastic leukemia (Review) 103
Phosphatidylinositol 3-kinase inhibition potentiates glucocorticoid response in B-cell acute lymphoblastic leukemia 100
Targeting phosphatidylinositol 3-kinase signaling in acute myelogenous leukemia 98
C033 Quantification of phosphoinositidephospholipase C (PI-PLC) beta 1 gene promoter methylation predicts the responsiveness to azacitidine in myelodysplastic syndromes 96
Phospholipase C-β1 interacts with cyclin E in adipose- derived stem cells osteogenic differentiation 95
The emerging role of the phosphatidylinositol 3-kinase/Akt/mTOR signaling network in normal myelopoieis and leukemogenesis 95
Expression of a functional CCR7 chemokine receptor inhibits the post-intravasation steps of metastasis in malignant murine mammary cancer cells 94
The phosphatidylinositol 3-kinase/AKT/mammalian target of rapamycin signaling network and the control of normal myelopoiesis 93
C025 Role of lipid signaling pathways in the response to erythropoietin in low risk MDS patients 93
PI3K/AKT/mTORC1 and MEK/ERK signaling in T-cell acute lymphoblastic leukemia: new options for targeted therapy 93
Development and 3D Printing of AESO-Based Composites Containing Olive Pit Powder 74
The Association Between Muscle Strength, Body Cell Mass, and Training Session Hours in Young Female Artistic Gymnasts: A Pilot Study 64
New agents and approaches for targeting the RAS/RAF/MEK/ERK and PI3K/AKT/mTOR cell survival pathways 64
Thermally stable strontium- and magnesium-enriched bioactive glass scaffolds promote bone regeneration and angiogenesis: An in vivo comparative study with 45S5 23
Totale 14.632
Salva come PNG Salva come JPEG
Categoria #
all - tutte 78.481
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 78.481
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/202261 0 0 0 13 2 4 2 6 6 7 13 8
2022/2023514 5 7 11 24 41 66 30 61 94 19 58 98
2023/2024871 35 26 37 145 120 64 173 60 20 28 86 77
2024/20253.810 83 19 13 227 848 625 109 143 385 125 608 625
2025/20267.687 707 634 1.099 876 661 387 864 280 638 654 389 498
2026/20271.403 243 419 446 295 0 0 0 0 0 0 0 0
Totale 14.638